| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-09 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-09 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-09 |
| mRNA | indisulam | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-09 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.19 | 5e-09 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 8e-09 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.18 | 1e-08 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-08 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-08 |